Weekly Digest – August 2026 Weekly Digest – August 2026 19 August 2026: GSK’s Blenrep combination approved in Singapore for treatment of relapsed/refractory Multiple myeloma GSK announced that Singapore’s Health Sciences Authority has approved Blenrep in combination with bortezomib plus […]
Weekly Digest – August 2026 Weekly Digest – August 2026 21 August 2026: Akeso’s AK157D1 cleared for phase 1 trial in Solid tumors Akeso announced that its B7-H3-targeted ADC candidate AK157D1 has been cleared by China’s NMPA Center for Drug […]
Weekly Digest – August 2026 Weekly Digest – August 2026 21 August 2026: CStone Pharmaceuticals receives NMPA IND approval for CS5007 CStone Pharmaceuticals announced that China’s NMPA has approved the IND application for CS5007, an EGFR/HER3 bispecific ADC, through the […]
Weekly Digest – August 2026 Weekly Digest – August 2026 17 August 2026: Enhertu significantly improved PFS as 1L treatment in HER2-mutant advanced NSCLC in the phase 3 DESTINY-Lung04 trial AstraZeneca and Daiichi Sankyo announced that Enhertu demonstrated a statistically […]
Weekly Digest – August 2026 Weekly Digest – August 2026 18 August 2026: Iza-bren phase 3 trial met its primary endpoint in locally advanced/metastatic NSCLC Biokin announced that the phase 3 BL-B01D1-301 trial of Iza-bren met its pre-specified primary endpoint of […]
Weekly Digest – August 2026 Weekly Digest – August 2026 20 August 2026: Akiram Therapeutics and ITM signed a Lu-177 supply agreement to support AKIR001 development in Solid tumors Akiram Therapeutics and ITM Isotope Technologies Munich have signed an agreement […]
